The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...

The findings? Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study's findings, what sets these drugs ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

According to the study, participants taking Zepbound lost an average of 20.2% of their starting weight after 72 weeks, ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

A preliminary study on popular weight loss drugs finds participants shed more weight on Zepbound than on Novo Nordisk’s Wegovy, Zepbound maker Eli Lilly said.

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...

FDA approves Zepbound for obstructive sleep apnea in obese individuals Discover how this weight-loss drug reduces symptoms ...